427 related articles for article (PubMed ID: 30830656)
1. Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Feng C; Wu M; Chen Z; Yu X; Nie Z; Zhao Y; Bao B
Int Urol Nephrol; 2019 Apr; 51(4):655-669. PubMed ID: 30830656
[TBL] [Abstract][Full Text] [Related]
2. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A protocol for systematic review and meta-analysis.
Yu B; Dong C; Hu Z; Liu B
Medicine (Baltimore); 2021 Feb; 100(8):e24655. PubMed ID: 33663074
[TBL] [Abstract][Full Text] [Related]
3. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Bae JH; Park EG; Kim S; Kim SG; Hahn S; Kim NH
Sci Rep; 2019 Sep; 9(1):13009. PubMed ID: 31506585
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis.
Seidu S; Kunutsor SK; Cos X; Gillani S; Khunti K;
Prim Care Diabetes; 2018 Jun; 12(3):265-283. PubMed ID: 29482993
[TBL] [Abstract][Full Text] [Related]
5. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
[TBL] [Abstract][Full Text] [Related]
6. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis.
Wang C; Zhou Y; Kong Z; Wang X; Lv W; Geng Z; Wang Y
Diabetes Obes Metab; 2019 Apr; 21(4):1018-1026. PubMed ID: 30565382
[TBL] [Abstract][Full Text] [Related]
7. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
[TBL] [Abstract][Full Text] [Related]
8. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
[TBL] [Abstract][Full Text] [Related]
9. Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Effect of SGLT2 Inhibitor on Blood Leptin and Adiponectin Level in Patients with Type 2 Diabetes.
Wu P; Wen W; Li J; Xu J; Zhao M; Chen H; Sun J
Horm Metab Res; 2019 Aug; 51(8):487-494. PubMed ID: 31408894
[TBL] [Abstract][Full Text] [Related]
10. The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: a systematic review and meta-analysis of randomized controlled trials.
Gohari S; Ismail-Beigi F; Mahjani M; Ghobadi S; Jafari A; Ahangar H; Gohari S
BMC Endocr Disord; 2023 Nov; 23(1):257. PubMed ID: 37996879
[TBL] [Abstract][Full Text] [Related]
11. Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: A systematic review and meta-analysis of observational studies.
Forbes AK; Suckling RJ; Hinton W; Feher MD; Banerjee D; Cole NI; de Lusignan S; Swift PA
Diabetes Obes Metab; 2023 Aug; 25(8):2310-2330. PubMed ID: 37202870
[TBL] [Abstract][Full Text] [Related]
12. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
Jardine M; Zhou Z; Lambers Heerspink HJ; Hockham C; Li Q; Agarwal R; Bakris GL; Cannon CP; Charytan DM; Greene T; Levin A; Li JW; Neuen BL; Neal B; Oh R; Oshima M; Pollock C; Wheeler DC; de Zeeuw D; Zhang H; Zinman B; Mahaffey KW; Perkovic V
Clin J Am Soc Nephrol; 2021 Mar; 16(3):384-395. PubMed ID: 33619120
[TBL] [Abstract][Full Text] [Related]
13. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Seidu S; Kunutsor SK; Topsever P; Khunti K
Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00303. PubMed ID: 34636161
[TBL] [Abstract][Full Text] [Related]
14. Comparative safety of sodium-glucose co-transporter 2 inhibitors in elderly patients with type 2 diabetes mellitus and diabetic kidney disease: a systematic review and meta-analysis.
Liu Y; An C; Liu P; Yang F; Zhao Q
Ren Fail; 2023 Dec; 45(1):2217287. PubMed ID: 37246403
[TBL] [Abstract][Full Text] [Related]
15. The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Luo Y; Lu K; Liu G; Wang J; Laurent I; Zhou X
Clin Drug Investig; 2018 Dec; 38(12):1089-1108. PubMed ID: 30255388
[TBL] [Abstract][Full Text] [Related]
16. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
Chen Z; Li G
Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606
[TBL] [Abstract][Full Text] [Related]
17. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
EMPA-KIDNEY Collaborative Group
Lancet Diabetes Endocrinol; 2024 Jan; 12(1):39-50. PubMed ID: 38061371
[TBL] [Abstract][Full Text] [Related]
18. Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Bae JH; Kim S; Park EG; Kim SG; Hahn S; Kim NH
Endocrinol Metab (Seoul); 2019 Mar; 34(1):80-92. PubMed ID: 30912341
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Neuen BL; Young T; Heerspink HJL; Neal B; Perkovic V; Billot L; Mahaffey KW; Charytan DM; Wheeler DC; Arnott C; Bompoint S; Levin A; Jardine MJ
Lancet Diabetes Endocrinol; 2019 Nov; 7(11):845-854. PubMed ID: 31495651
[TBL] [Abstract][Full Text] [Related]
20. Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.
Wang H; Yang J; Chen X; Qiu F; Li J
Clin Ther; 2019 Feb; 41(2):322-334.e11. PubMed ID: 30711143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
